Curis Inc (CRIS)

$6.12

+0.1

(+1.66%)▲

Market is closed - opens 7 PM, 29 Jul 2024

Performance

  • $6.00
    $6.28
    $6.12
    downward going graph

    1.96%

    Downside

    Day's Volatility :4.46%

    Upside

    2.55%

    downward going graph
  • $3.80
    $17.49
    $6.12
    downward going graph

    37.91%

    Downside

    52 Weeks Volatility :78.27%

    Upside

    65.01%

    downward going graph

Returns

PeriodCuris IncSector (Health Care)Index (Russel 2000)
3 Months
-58.4%
6.5%
0.0%
6 Months
-41.5%
7.1%
0.0%
1 Year
-62.37%
9.8%
0.0%
3 Years
-95.97%
14.2%
-20.2%

Highlights

Market Capitalization
36.7M
Book Value
$1.61
Earnings Per Share (EPS)
-8.34
PEG Ratio
0.0
Wall Street Target Price
22.5
Profit Margin
0.0%
Operating Margin TTM
-597.75%
Return On Assets TTM
-39.26%
Return On Equity TTM
-207.29%
Revenue TTM
9.8M
Revenue Per Share TTM
1.77
Quarterly Revenue Growth YOY
-9.2%
Gross Profit TTM
-33.4M
EBITDA
-48.9M
Diluted Eps TTM
-8.34
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-6.15
EPS Estimate Next Year
-4.58
EPS Estimate Current Quarter
-2.12
EPS Estimate Next Quarter
-1.87

Analyst Recommendation

Buy
    83%Buy
    16%Hold
    0
    0%Sell
Based on 12 Wall street analysts offering stock ratings for Curis Inc(by analysts ranked 0 to 5 stars)
Based on 12 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
10
10
10
Hold
2
2
2
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 267.65%

Current $6.12
Target $22.50

Company Financials

FY18Y/Y Change
Revenue
10.4M
↑ 5.35%
Net Income
-32.6M
↓ 38.9%
Net Profit Margin
-312.38%
↑ 226.28%
FY19Y/Y Change
Revenue
10.0M
↓ 4.07%
Net Income
-36.8M
↑ 12.98%
Net Profit Margin
-367.89%
↓ 55.51%
FY20Y/Y Change
Revenue
10.8M
↑ 8.31%
Net Income
-34.9M
↓ 5.22%
Net Profit Margin
-321.93%
↑ 45.96%
FY21Y/Y Change
Revenue
10.6M
↓ 1.72%
Net Income
-50.6M
↑ 45.18%
Net Profit Margin
-475.54%
↓ 153.61%
FY22Y/Y Change
Revenue
10.2M
↓ 4.57%
Net Income
-60.3M
↑ 19.12%
Net Profit Margin
-593.62%
↓ 118.08%
FY23Y/Y Change
Revenue
10.0M
↓ 1.37%
Net Income
-47.4M
↓ 21.4%
Net Profit Margin
-473.04%
↑ 120.58%
Q4 FY22Q/Q Change
Revenue
2.9M
↑ 2.19%
Net Income
-12.4M
↓ 11.04%
Net Profit Margin
-430.83%
↑ 64.11%
Q1 FY23Q/Q Change
Revenue
2.3M
↓ 20.44%
Net Income
-11.5M
↓ 7.61%
Net Profit Margin
-500.26%
↓ 69.43%
Q2 FY23Q/Q Change
Revenue
2.2M
↓ 4.35%
Net Income
-12.0M
↑ 4.09%
Net Profit Margin
-544.42%
↓ 44.16%
Q3 FY23Q/Q Change
Revenue
2.8M
↑ 28.95%
Net Income
-12.2M
↑ 1.84%
Net Profit Margin
-429.97%
↑ 114.45%
Q4 FY23Q/Q Change
Revenue
2.7M
↓ 4.84%
Net Income
-11.8M
↓ 3.29%
Net Profit Margin
-436.94%
↓ 6.97%
Q1 FY24Q/Q Change
Revenue
2.1M
↓ 22.63%
Net Income
-11.9M
↑ 0.81%
Net Profit Margin
-569.32%
↓ 132.38%
FY18Y/Y Change
Total Assets
37.4M
↓ 49.37%
Total Liabilities
41.9M
↓ 15.95%
FY19Y/Y Change
Total Assets
35.1M
↓ 6.04%
Total Liabilities
69.0M
↑ 64.87%
FY20Y/Y Change
Total Assets
204.4M
↑ 482.1%
Total Liabilities
73.7M
↑ 6.77%
FY21Y/Y Change
Total Assets
162.3M
↓ 20.58%
Total Liabilities
71.6M
↓ 2.84%
FY22Y/Y Change
Total Assets
108.8M
↓ 32.93%
Total Liabilities
62.3M
↓ 12.99%
FY23Y/Y Change
Total Assets
77.3M
↓ 29.0%
Total Liabilities
57.6M
↓ 7.52%
Q4 FY22Q/Q Change
Total Assets
108.8M
↓ 11.4%
Total Liabilities
62.3M
↓ 7.17%
Q1 FY23Q/Q Change
Total Assets
94.5M
↓ 13.14%
Total Liabilities
58.0M
↓ 6.97%
Q2 FY23Q/Q Change
Total Assets
84.3M
↓ 10.83%
Total Liabilities
58.1M
↑ 0.22%
Q3 FY23Q/Q Change
Total Assets
90.0M
↑ 6.72%
Total Liabilities
60.4M
↑ 3.96%
Q4 FY23Q/Q Change
Total Assets
77.3M
↓ 14.11%
Total Liabilities
57.6M
↓ 4.59%
Q1 FY24Q/Q Change
Total Assets
62.0M
↓ 19.74%
Total Liabilities
52.6M
↓ 8.77%
FY18Y/Y Change
Operating Cash Flow
-30.1M
↓ 37.82%
Investing Cash Flow
21.4M
↓ 688.82%
Financing Cash Flow
-6.0M
↓ 109.28%
FY19Y/Y Change
Operating Cash Flow
-26.2M
↓ 12.84%
Investing Cash Flow
-4.5M
↓ 120.85%
Financing Cash Flow
23.3M
↓ 490.39%
FY20Y/Y Change
Operating Cash Flow
-25.7M
↓ 1.78%
Investing Cash Flow
-49.0M
↑ 1000.72%
Financing Cash Flow
188.8M
↑ 711.37%
FY21Y/Y Change
Operating Cash Flow
-37.6M
↑ 46.16%
Investing Cash Flow
-47.9M
↓ 2.35%
Financing Cash Flow
-4.2M
↓ 102.21%
FY22Y/Y Change
Operating Cash Flow
-54.3M
↑ 44.44%
Investing Cash Flow
33.0M
↓ 168.95%
Financing Cash Flow
867.0K
↓ 120.78%
Q4 FY22Q/Q Change
Operating Cash Flow
-12.3M
↓ 6.51%
Investing Cash Flow
3.5M
↓ 19.52%
Financing Cash Flow
-1.4M
↓ 129.77%
Q1 FY23Q/Q Change
Operating Cash Flow
-12.2M
↓ 0.56%
Investing Cash Flow
26.2M
↑ 657.81%
Financing Cash Flow
-2.0M
↑ 44.52%
Q2 FY23Q/Q Change
Operating Cash Flow
-7.9M
↓ 35.5%
Investing Cash Flow
-3.2M
↓ 112.02%
Financing Cash Flow
-852.0K
↓ 57.53%

Technicals Summary

Sell

Neutral

Buy

Curis Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Curis Inc
Curis Inc
-19.73%
-41.5%
-62.37%
-95.97%
-87.14%
Moderna, Inc.
Moderna, Inc.
-1.67%
18.26%
-0.21%
-64.15%
752.69%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-0.46%
13.21%
45.59%
84.19%
244.2%
Novo Nordisk A/s
Novo Nordisk A/s
-11.0%
18.31%
61.56%
186.46%
423.59%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
3.85%
14.43%
39.88%
147.45%
195.07%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Curis Inc
Curis Inc
NA
NA
0.0
-6.15
-2.07
-0.39
NA
1.61
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-7.19
-0.38
-0.16
NA
33.47
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
31.35
31.35
1.46
44.44
0.15
0.08
NA
250.15
Novo Nordisk A/s
Novo Nordisk A/s
44.28
44.28
2.36
3.43
1.0
0.25
0.01
22.18
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
31.85
31.85
0.53
16.98
0.24
0.13
NA
71.8
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Curis Inc
Curis Inc
Buy
$36.7M
-87.14%
NA
0.0%
Moderna, Inc.
Moderna, Inc.
Buy
$45.3B
752.69%
24.73
-115.82%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$116.9B
244.2%
31.35
29.45%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$572.0B
423.59%
44.28
36.55%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$126.7B
195.07%
31.85
39.46%

Insights on Curis Inc

  • Decreasing Revenue

    Revenue is down for the last 3 quarters, 2.83M → 2.08M (in $), with an average decrease of 13.7% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 2 quarters, -11.78M → -11.87M (in $), with an average decrease of 0.8% per quarter

  • Vs NVO

    In the last 1 year, Novo Nordisk A/s has given 61.6% return, outperforming this stock by 124.0%

  • Vs NVO

    In the last 3 years, Novo Nordisk A/s has given 186.5% return, outperforming this stock by 282.5%

Institutional Holdings

  • Maverick Capital Ltd

    9.88%

  • M28 Capital Management LP

    7.16%

  • Kingdon Capital Management LLC

    4.82%

  • Vanguard Group Inc

    3.71%

  • CM Management, LLC

    2.04%

  • Citigroup Inc

    1.56%

Company Information

curis is a publicly-traded biotechnology company (nasdaq: cris) focused on the development and commercialization of innovative drug candidates for the treatment of human cancers. curis’s pipeline of drug candidates includes cudc-907, which is currently being investigating in clinical trials in patients with relapsed or refractory diffuse large b-cell lymphoma with alterations in the myc oncogene. curis is also engaged in a broad collaboration with aurigene in the areas of immuno-oncology and precision oncology. as part of this collaboration, curis has exclusive licenses to oral small molecule antagonists of the pd1 and vista pathways, including pdl1/vista antagonist ca-170, and oral small molecule antagonists of the pd1 and tim3 pathways, including pdl1/tim3 antagonist ca-327, as well as to molecules designed to inhibit the irak4 kinase, including ca-4948. ca-170 is currently undergoing testing in a phase 1 trial in patients with advanced solid tumors and lymphomas. ca-4948 is currentl

Organization
Curis Inc
Employees
49
CEO
Mr. James E. Dentzer
Industry
Health Technology

Discover More

FAQs